Literature DB >> 2291671

In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents.

T Yamamoto1, P Naigowit, S Dejsirilert, D Chiewsilp, E Kondo, T Yokota, K Kanai.   

Abstract

Clinical isolates of Pseudomonas pseudomallei isolated in Thailand from 1981 to 1989 were tested for their in vitro susceptibilities to 27 antimicrobial agents, including older and newer quinolones, broad-spectrum cephems, carbapenems, monobactams, penicillins, tetracyclines, chloramphenicol, rifamycin, sulfamethoxazole, trimethoprim, and fosfomycin. Tosufloxacin, meropenem, CS-533, and minocycline were active against P. pseudomallei at levels comparable to or even greater than those of antimicrobial agents tested in previous studies, such as ciprofloxacin, ceftazidime, imipenem, carumonam, and piperacillin. Drug-resistant P. pseudomallei was found in only 1% of the isolates. The drug-resistant P. pseudomallei isolates displayed a unique pattern of susceptibility to the above-listed drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291671      PMCID: PMC171985          DOI: 10.1128/AAC.34.10.2027

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer beta-lactam antibiotics and quinolone derivatives.

Authors:  P Y Chau; W S Ng; Y K Leung; S Lolekha
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

3.  In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.

Authors:  H C Neu; N X Chin; G Saha; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

4.  Antibiotic resistance in Pseudomonas pseudomallei.

Authors:  D A Dance; V Wuthiekanun; N J White; W Chaowagul
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

5.  In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.

Authors:  K Fujimaki; T Noumi; I Saikawa; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

7.  In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity.

Authors:  N Watanabe; K Katsu; M Moriyama; K Kitoh
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 8.  Aspects of chemistry in the development of the 4-quinolone antibacterial agents.

Authors:  G C Crumplin
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

9.  Susceptibility of Pseudomonas pseudomallei to new beta-lactam and aminoglycoside antibiotics.

Authors:  D W McEniry; S H Gillespie; D Felmingham
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

10.  Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

Authors:  D J Hardy; R N Swanson; D M Hensey; N R Ramer; R R Bower; C W Hanson; D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

View more
  4 in total

1.  Genetic control of weight loss during pneumonic Burkholderia pseudomallei infection.

Authors:  Felicia D Emery; Jyothi Parvathareddy; Ashutosh K Pandey; Yan Cui; Robert W Williams; Mark A Miller
Journal:  Pathog Dis       Date:  2014-04-22       Impact factor: 3.166

Review 2.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Outcomes of patients with melioidosis treated with meropenem.

Authors:  Allen C Cheng; Dale A Fisher; Nicholas M Anstey; Dianne P Stephens; Susan P Jacups; Bart J Currie
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Clinical features and laboratory diagnosis of infection with the potential bioterrorism agents burkholderia mallei and burkholderia pseudomallei.

Authors:  Jacob Gilad; David Schwartz; Yoram Amsalem
Journal:  Int J Biomed Sci       Date:  2007-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.